Kinfo
Agenus Inc. logo

Agenus Inc.

AGENNASDAQHealthcare·US · USD
$3.14
-0.11 (-3.24%)
Prices as of July 10, 2026 · live

Price

Key statistics

Valuation
Market cap134.92M USD
Enterprise value134.65M USD
Trailing P/E1.59
Forward P/E-1.42
PEG ratio-0.01
Price / sales1.10
Price / book-0.52
Profitability
Gross margin64.96%
Operating margin44.62%
Profit margin52.16%
Return on assets2.53%
Return on equity0.04%
Income (TTM)
Revenue123.87M USD
Gross profit120.64M USD
EBITDA15.19M USD
Net income64.39M USD
Diluted EPS$2.05
Rev. growth (YoY)40.20%
Balance sheet
Total cash35.00M USD
Total debt41.07M USD
Debt / equity-0.18
Current ratio0.38
Book value / share-$5.74
Cash flow (TTM)
Operating cash flow-87.53M USD
Levered free cash flow-53.02M USD
Shares & price
Shares outstanding38.52M
Float38.86M
Held by institutions23.55%
Beta1.55
50-day MA$3.38
200-day MA$3.65
52-week high$7.34
52-week low$2.71
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-11-0.33-0.09+72.73%2026-05-111.80-0.03−101.67%2026-03-16-1.05-0.37+64.76%2026-02-100.961.00+4.17%2025-11-102.20-1.16−152.73%
About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies to treat cancer and infectious diseases. The company specializes in activating the body's immune system through advanced therapeutic approaches, operating both in the United States and internationally. Agenus develops a diverse pipeline of immunotherapy candidates, including its lead program combining botensilimab and balstilimab for cancer treatment, alongside other investigational therapies targeting various oncology and infectious disease indications. The company leverages proprietary technologies including its Retrocyte Display platform for antibody identification and development. Agenus has established strategic partnerships to advance its manufacturing capabilities and expand access to its therapeutic candidates. The company's approach emphasizes immunooncology and the development of novel treatment modalities to address significant unmet medical needs in cancer care and infectious disease management.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Garo H. Armen Ph.D.
Employees
81
Headquarters
Lexington, MA, United States

Frequently asked questions about Agenus Inc.